The Primary Immune Deficiency Treatment Consortium: how can it improve definitive therapy for PID?

Click to increase image sizeClick to decrease image size

Acknowledgments

There are many people who are responsible for the establishment and functioning of the PIDTC including the members of the Steering Committee (Luigi Notarangelo (co-PI), Jennifer Puck, Don Kohn and Linda Griffith (NIAID Medical Officer)), the members of the Scientific Planning Committee that includes the center PI’s, the Patient Advocacy Groups (Marcia Boyle and Barb Ballard, IDF; Heather Smith, SCID Angels for Life; Sumathi Iyengar, Wiskott Aldrich Foundation; Mary Hurley, CGD Association; Fred and Vicki Modell, Jeffrey Modell Foundation) and the project managers (Elizabeth Dunn, Tara Bani, and Megan Murnane). Special thanks to Jennifer Puck (UCSF) and Linda Griffith (NIAID, NIH) for their careful editing and thoughtful comments.

The Primary Immune Deficiency Treatment Consortium (U54-AI082973) is part of Rare Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS). The PIDTC is funded by the National Institute of Allergy and Infectious Diseases (NIAID), NCATS-ORDR, and, NIH. The PIDTC Annual Scientific Workshop is funded in part by a grant from the NIAID (R13 AI094943) with supplemental funding from the ORDR, NCATS.

Declaration of interest

MJ Cowan is on the Scientific Advisory Boards for Exogen Bio, Inc and Homology Medicine, Inc and the Data Safety Review Board for Bluebird Bio, Inc. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

MJ Cowan receives partial salary support from grants from National Institute of Allergy and Infectious Diseases (U54-AI082973) and the California Institute of Regenerative Medicine (CLIN1-08363 and DR2-05365).